Clear Wave Wealth Management LLC Acquires New Shares in Moderna, Inc. $MRNA

Clear Wave Wealth Management LLC bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 2,069 shares of the company’s stock, valued at approximately $398,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Moderna during the 2nd quarter valued at $2,142,877,000. Theleme Partners LLP bought a new position in Moderna in the 2nd quarter worth $564,272,000. Wellington Management Group LLP lifted its position in shares of Moderna by 4.4% in the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after purchasing an additional 103,977 shares during the period. First Trust Advisors LP lifted its position in shares of Moderna by 59.3% in the 1st quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after purchasing an additional 891,072 shares during the period. Finally, Merck & Co. Inc. purchased a new stake in shares of Moderna in the 2nd quarter worth about $161,642,545. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 39,145 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This represents a 2.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 197,251 shares of company stock valued at $33,875,904. Company insiders own 10.80% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Raised outlook and improved results: Moderna lifted its 2026 revenue-growth forecast to 15%–25% after a Q3 beat, citing lower costs and gains from respiratory vaccines. Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
• Positive Sentiment: Oncology pipeline milestone: Phase 3 data for personalized cancer therapy intismeran showed a 42% reduction in melanoma recurrence or death risk. Moderna aims to file with the FDA by year-end 2026, potentially setting up a decision in 2027. Can Moderna’s First Cancer Therapy Win FDA Approval in 2027?
• Positive Sentiment: Moderna’s collaboration with Tempus AI is among partnerships expected to generate about $192.5 million over five years, adding a potential source of revenue beyond vaccine sales. The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
• Neutral Sentiment: Analysts raised one fair-value estimate from $135.84 to $145.42, reflecting improved Q3 execution and intismeran’s potential, while noting uncertainty about future COVID and oncology revenue. Moderna Stock Fair Value Rises After Intismeran Data And Q3 Beat
• Negative Sentiment: Revenue concentration and valuation risk: Nearly all revenue still comes from COVID-related products, leaving Moderna exposed to demand changes. Goldman Sachs raised its target to $195 but kept a neutral rating; that target and the cited fair-value estimate are both below the $269 price in the provided market data. Moderna’s Q3 Numbers May Have Seemed Impressive, but They Aren’t Enough to Make the Stock a Buy

Moderna Stock Performance

Shares of MRNA stock opened at $269.00 on Tuesday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average price of $194.47 and a 200-day moving average price of $92.61. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $280.80. The firm has a market capitalization of $107.40 billion, a PE ratio of -37.89 and a beta of 1.16.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. During the same quarter in the prior year, the firm earned ($0.51) earnings per share. The firm’s revenue for the quarter was up 29.2% compared to the same quarter last year. As a group, equities research analysts expect that Moderna, Inc. will post -6.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Morgan Stanley raised their price objective on shares of Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Moderna in a report on Friday, September 25th. Wolfe Research raised Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday, August 25th. Loop Capital set a $135.00 target price on Moderna in a research report on Wednesday, August 19th. Finally, Bradesco Corretora upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. Six equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Moderna has an average rating of “Hold” and an average target price of $113.75.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.